Business Integration and Operational Efficiency through the Absorption Merger of HMTバイオメディカル株式会社
First written in FY2021-Q1. 1 of 3 entries say "Achieved", first in FY2021-Q2. Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1ReframedAnnual report
「Beginning with the current interim consolidated accounting period, the Company changed its reportable segments from the two existing segments, “Advanced Research and Development Support Business” and “Healthcare Solutions Business,” to a single segment, “Contracted Metabolome Analysis Services Business.”」
The Company changed from the previous framework of reporting the two businesses separately to operating and reporting them in an integrated single segment. - FY2021-Q2AchievedAnnual report
「Under this agreement, the company absorbed HMTバイオメディカル株式会社 in a merger effective 1 January 2021.」
The absorption-type merger of HMTバイオメディカル株式会社, its wholly owned subsidiary, was completed effective 1 January 2021, completing the planned business integration. - FY2021-Q1First statedAnnual report
「At a meeting of its Board of Directors held on 11 November 2020, the Company resolved to conduct an absorption-type merger with its wholly owned subsidiary HMTバイオメディカル株式会社 and entered into a merger agreement on the same date. The business combination date is scheduled for 1 January 2021. The merger is intended to enhance corporate value by promoting research and business development through closer coordination between the two businesses and by improving operational efficiency.」
The Company disclosed for the first time its plan to absorb HMTバイオメディカル株式会社, its wholly owned subsidiary, effective 1 January 2021, with the aim of strengthening coordination between the metabolomics and biomarker businesses, promoting research and business development, and improving operational efficiency.